Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.

Silva RLE, Kanan Y, Mirando AC, Kim J, Shmueli RB, Lorenc VE, Fortmann SD, Sciamanna J, Pandey NB, Green JJ, Popel AS, Campochiaro PA.

Sci Transl Med. 2017 Jan 18;9(373). pii: eaai8030. doi: 10.1126/scitranslmed.aai8030.

2.

A biomimetic collagen derived peptide exhibits anti-angiogenic activity in triple negative breast cancer.

Rosca EV, Penet MF, Mori N, Koskimaki JE, Lee E, Pandey NB, Bhujwalla ZM, Popel AS.

PLoS One. 2014 Nov 10;9(11):e111901. doi: 10.1371/journal.pone.0111901. eCollection 2014.

3.
4.

Vascular wall extracellular matrix proteins and vascular diseases.

Xu J, Shi GP.

Biochim Biophys Acta. 2014 Nov;1842(11):2106-2119. doi: 10.1016/j.bbadis.2014.07.008. Epub 2014 Jul 18. Review.

5.

A systems biology view of blood vessel growth and remodelling.

Logsdon EA, Finley SD, Popel AS, Mac Gabhann F.

J Cell Mol Med. 2014 Aug;18(8):1491-508. doi: 10.1111/jcmm.12164. Epub 2013 Nov 17. Review.

6.

Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors.

Koskimaki JE, Lee E, Chen W, Rivera CG, Rosca EV, Pandey NB, Popel AS.

Angiogenesis. 2013 Jan;16(1):159-70. doi: 10.1007/s10456-012-9308-7. Epub 2012 Sep 29.

7.

Scavenger receptor class B type I is a plasma membrane cholesterol sensor.

Saddar S, Carriere V, Lee WR, Tanigaki K, Yuhanna IS, Parathath S, Morel E, Warrier M, Sawyer JK, Gerard RD, Temel RE, Brown JM, Connelly M, Mineo C, Shaul PW.

Circ Res. 2013 Jan 4;112(1):140-51. doi: 10.1161/CIRCRESAHA.112.280081. Epub 2012 Sep 28.

8.

Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth.

Rosca EV, Lal B, Koskimaki JE, Popel AS, Laterra J.

Anticancer Drugs. 2012 Aug;23(7):706-12. doi: 10.1097/CAD.0b013e3283531041.

9.

Structure-activity relationship study of collagen-derived anti-angiogenic biomimetic peptides.

Rosca EV, Koskimaki JE, Pandey NB, Tamiz AP, Popel AS.

Chem Biol Drug Des. 2012 Jul;80(1):27-37. doi: 10.1111/j.1747-0285.2012.01376.x. Epub 2012 Apr 27.

10.

Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer.

Rosca EV, Koskimaki JE, Pandey NB, Wolff AC, Popel AS.

Cancer Biol Ther. 2011 Nov 1;12(9):808-17. doi: 10.4161/cbt.12.9.17677. Epub 2011 Nov 1.

11.

Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity.

Rivera CG, Rosca EV, Pandey NB, Koskimaki JE, Bader JS, Popel AS.

J Med Chem. 2011 Oct 13;54(19):6492-500. doi: 10.1021/jm200114f. Epub 2011 Sep 13.

12.

Angiogenesis-associated crosstalk between collagens, CXC chemokines, and thrombospondin domain-containing proteins.

Rivera CG, Bader JS, Popel AS.

Ann Biomed Eng. 2011 Aug;39(8):2213-22. doi: 10.1007/s10439-011-0325-2. Epub 2011 May 18.

13.

Anti-angiogenic peptides for cancer therapeutics.

Rosca EV, Koskimaki JE, Rivera CG, Pandey NB, Tamiz AP, Popel AS.

Curr Pharm Biotechnol. 2011 Aug;12(8):1101-16. Review.

Supplemental Content

Support Center